First Russian DPP-4 inhibitor Gosogliptin comparing to Vildagliptin in type 2 diabetes mellitus patients

Código QR

First Russian DPP-4 inhibitor Gosogliptin comparing to Vildagliptin in type 2 diabetes mellitus patients

Introduction.In the early 2000s, in type 2 diabetes mellitus (T2DM) treatment, a fundamentally new class of drugs appeared—the incretin mimetics. The use of dipeptidyl peptidase-4 (DPP-4) inhibitors allowed the safety of the T2DM therapy to be increased by reducing several parameters, including hypo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Karina Oganesovna Galstyan, Liudmila Viktorovna Nedosugova, Nina Alexandrovna Petunina, Julia Alexandrovna Trakhtenberg, Natalia Vadimovna Vostokova, Oksana Vladimirovna Karavaeva, Tatiana Evgenievna Chasovskaya
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2016
Materias:	diabetes mellitus type 2 glycated hemoglobin нbа1с dpp-4 inhibitor gosogliptin vildagliptin Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/5f62c58ac7554d608a2ddc46a781c7e3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Initial investigation of efficacy and safety of a new dipeptidyl peptidase-4 inhibitor, gosogliptin, for type 2 diabetes in Russia
por: Lyudmila Viktorovna Nedosugova, et al.
Publicado: (2014)

Vildagliptin: the first innovative DDP-4 inhibitor
por: Edvin Villkhauer
Publicado: (2010)

Clinical implementetion of vildagliptin: data from recent studies comparing incretin-based medications
por: Elena Valer'evna Biryukova
Publicado: (2014)

THE SYSTEMIC CRISIS OF THE CIVILIZATION OF THE WEST IN UNDERSTANDING OF MODERN RUSSIAN AND FOREIGN SCIENTISTS – COMPARATIVE ANALYSIS
por: Ilya Leonidovich Morozov
Publicado: (2017)

EDGE study in Russian Federation: efficacy and safety of vildagliptine in comparison with other oral antidiabetic agents in patients with type 2 diabetes mellitus
por: Gagik Radikovich Galstyan
Publicado: (2013)

The Russian Memoirs About Battle at Austerlitz
por: S. P. Ribakov
Publicado: (2012)

STUDY OF THE EXISTING SYSTEM OF EQUITY CONSTRUCTION INVOLVING INDIVIDUALS INVESTMENT IN REАL ESTАTE AND ITS DEVELOPMENT PROSPECTS
por: V. A. Opekunov, et al.
Publicado: (2020)

Expert committee on introduction of incretin-based therapy in Russia: advance and failure
por: Editorial team Diabetes Mellitus
Publicado: (2012)

Nanofibrous vildagliptin-eluting stents enhance re-endothelialization and reduce neointimal formation in diabetes: in vitro and in vivo
por: Lee CH, et al.
Publicado: (2019)

DEVELOPMENT AND VALIDATION OF SPECTROPHOTOMETRIC METHODS FOR THE DETERMINATION AND SPECTROSCOPIC CHARACTERIZATION OF VILDAGLIPTIN USING II -ACCEPTORS IN PHARMACEUTICAL PREPARATIONS
por: TEKKELI,SERIFE EVRIM KEPEKCI, et al.
Publicado: (2014)

The efficacy of therapy with DPP-4 inhibitors combined with insulin in patients with type 2 diabetes mellitus
por: Alexander Sergeevich Ametov, et al.
Publicado: (2011)

Vildagliptin: optimal control in type 2 diabetes mellitus treatment
por: Alexander Sergeevich Ametov
Publicado: (2015)

Effects of vildagliptin relative to sulfonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: influence of age and treatment with/without metformin in the VIRTUE study
por: Hassoun AAK, et al.
Publicado: (2016)

GENETIC POLYMORPHISMS OF CD14, TNFα AND FCGR2A IN THE PATIENTS WITH INFLUENZA A H1N1 IN TRANSBAIKALIA REGION
por: V. V. Petrov, et al.
Publicado: (2014)

Vildagliptin and its role in the treatment of diabetes mellitus
por: Yury Shavkatovich Khalimov
Publicado: (2010)

Results of a clinical trial of the efficacy and safety of vildagliptin and metformin fixed combination in real clinical practice in Russia (MASTER study)
por: N. A. Demidov, et al.
Publicado: (2021)

Long-Term Glycaemic Durability of Early Combination Therapy Strategy versus Metformin Monotherapy in Korean Patients with Newly Diagnosed Type 2 Diabetes Mellitus
por: Soon-Jib Yoo, et al.
Publicado: (2021)

Efficacious and safe management of type 2 diabetes mellitus using DPP-4 inhibitors
por: Alexander Sergeevich Ametov, et al.
Publicado: (2010)

Expert committee on novel DPP-4 inhibitor TRADJENTA (linagliptin) in treatment of type 2 diabetes mellitus
por: Editorial team Diabetes Mellitus
Publicado: (2012)

Possible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy
por: Gagik Radikovich Galstyan, et al.
Publicado: (2015)

Professor S.A.Abusuev (on 60th anniversary)
por: Editorial team Diabetes Mellitus
Publicado: (2000)

LOCАL GOVЕRNMЕNT: BUDGЕT MАNАGЕMЕNT РЕRFORMАNCЕ. CАSЕ STUDУ: RЕРUBLIC OF MOLDOVА
por: Ion Cozmа, et al.
Publicado: (2021)

Antikvari između prirode i kulture
por: Vladimir V. Mihajlović
Publicado: (2017)

CLONING, EXPRESSION AND STLJDY OF IMMIJNOLOGICAL PROPERTIES OF THE STREPTOCOCCI GROUP B C5A PEPTIDASE RECOMBINANT PROTEIN
por: N. V. Duplik, et al.
Publicado: (2014)

«The black room» the Russian foreign Ministry against Napoleon
por: D. E. Larin
Publicado: (2012)

Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program
por: Marina Vladimirovna Shestakova
Publicado: (2010)

DPP4 Regulates DHCR24-Mediated Cholesterol Biosynthesis to Promote Methotrexate Resistance in Gestational Trophoblastic Neoplastic Cells
por: Weijie Yuan, et al.
Publicado: (2021)

The Munich Conference and the Soviet-German Non-Aggression Pact in the Discussions of Russian Historians
por: V. P. Smirnov
Publicado: (2009)

Dysregulation of DPP4 Is Associated with the AMPK/JAK2/STAT3 Pathway in Adipocytes Under Insulin Resistance Status and Liraglutide Intervention
por: Cheng F, et al.
Publicado: (2019)

What are new opportunities for clinical practice the VERIFY study opens and which values for native diabetes patients? Joint conclusion on the advisory board results. November 6, 2019
por: Marina V. Shestakova, et al.
Publicado: (2020)

Add-On Therapy with DPP-4 Inhibitors May Improve Renal Function Decline in α-Glucosidase Inhibitor and Metformin Users: A Retrospective Observational Study
por: Osonoi T, et al.
Publicado: (2020)

Dysregulation of DPP4-CXCL12 Balance by TGF-β1/SMAD Pathway Promotes CXCR4+ Inflammatory Cell Infiltration in Keloid Scars
por: Chen Z, et al.
Publicado: (2021)

Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin
por: Russo E, et al.
Publicado: (2013)

Sequential alcalase and flavourzyme treatment for preparation of α-amylase, α-glucosidase, and dipeptidyl peptidase (DPP)-IV inhibitory peptides from oat protein
por: Lourdes Ramírez Fuentes, et al.
Publicado: (2021)

Opyt klinicheskogo primeneniya preparatov Biosulin? R i Biosulin? N v respublike Bashkortostan
por: M G Davydovich, et al.
Publicado: (2007)

DPP-4 Inhibitors Have Different Effects on Endothelial Low-Grade Inflammation and on the M1-M2 Macrophage Polarization Under Hyperglycemic Conditions
por: De Nigris V, et al.
Publicado: (2021)

QUANTITATION OF LAMIVUDINE BY UV SPECTROPHOTOMETRY
por: Y. A. Gonchikova, et al.
Publicado: (2017)

Angioedema in a Patient with Autoimmune Thyroiditis – A Case Report
por: Dermendzhiev S., et al.
Publicado: (2020)

Dipeptidyl Peptidase Inhibition Enhances CD8 T Cell Recruitment and Activates Intrahepatic Inflammasome in a Murine Model of Hepatocellular Carcinoma
por: James M. Henderson, et al.
Publicado: (2021)

International guidelines on the study of glycated hemoglobin HbA1c level as a diagnostic criterion for diabetes mellitus and otherdisorders of carbohydrate metabolism
por: Gagik Radikovich Galstyan
Publicado: (2010)